Technology
Health
Biotechnology

Coherus BioSciences

$18.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (1.35%) As of 3:41 PM EDT today
+$0.24 (1.35%) Today

Why Robinhood?

You can buy or sell CHRS and other stocks, options, ETFs, and crypto commission-free!

About CHRS

Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Read More Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Employees
232
Headquarters
Redwood City, California
Founded
2010
Market Cap
1.23B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.57M
High Today
$18.24
Low Today
$17.51
Open Price
$17.73
Volume
429.09K
52 Week High
$23.43
52 Week Low
$8.32

Collections

Technology
Health
Biotechnology
Medical
Therapy
2014 IPO
US
North America

CHRS News

BenzingaJul 8

Coherus BioSciences Shares Fall Following Q2 Sales Guidance

96

CHRS Earnings

-$0.92
-$0.71
-$0.50
-$0.29
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 1, After Hours

More CHRS News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.